Topic：Sinopharm Group

Unhidea explains global investment research, selected interviews and market briefs. Explore source attribution, dates, key assumptions and the reasoning behind each article.

Sinopharm Group’s third-quarter revenue decline narrows as cost controls drive profit growth

In the third quarter of 2026, Sinopharm Group’s revenue fell 0.4% year on year, though the decline narrowed from the second quarter; profit rose 3.7% year on year. Goldman Sachs raised its earnings forecasts while maintaining a Neutral rating.

Goldman Sachs · 2026.10.30 02:29

Sinopharm Group’s third-quarter revenue misses expectations, while lower expenses lift profit above forecasts

Third-quarter revenue edged down year on year and fell short of the Bloomberg consensus; lower selling, other and interest expenses drove growth in profit attributable to shareholders. Nomura maintains its Buy rating.

Nomura · 2026.10.30 02:29